Immunome, Inc.
NASDAQ:IMNM · NASDAQ Capital Market
-$0.42 today
Vol 2.54M · Avg 1.23M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-33.5%
avg -67.4%
ROIC
-33.5%
avg -134.2%
ROA
-31.1%
avg -105.7%
Analysis
ROA is currently the strongest return metric at -31.1% versus its period average of -105.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Clay Siegall | Chairman, President & Chief Executive Officer | $1.41M | — | 65 | $690,704.00 | 0.72% |
Max Rosett | Chief Financial Officer | $1.16M | — | 36 | $54,037.00 | 0.06% |
Jack Higgins | Chief Scientific Officer | $956,342.00 | — | 46 | $22,000.00 | 0.02% |
Robert J. Lechleider | Chief Medical Officer | $850,093.00 | — | 65 | $242,000.00 | 0.25% |
Sandra G. Stoneman | Chief Legal Officer, General Counsel & Corporate Secretary | $715,350.00 | — | 53 | $9,897.00 | 0.01% |
Kinney Horn | Chief Business Officer | $598,862.00 | — | 51 | $161,000.00 | 0.17% |
Roee Shahar | Executive Vice President of Commercial | — | — | — | — | — |
Philip Tsai | Chief Technical Officer | — | — | 58 | $9,897.00 | 0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
11
$2.31M
Sells
10
$12.59M
Net Sentiment
$10.29M
Net selling
Most Active
BIENAIME JEAN JACQUES
8 transactions
1–10 of 21
Analysis
Insiders reported 11 buys worth $2.31M and 10 sells worth $12.59M over the last 12 months. That adds up to net selling of $10.29M. BIENAIME JEAN JACQUES was the most active insider with 8 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | N/A | N/A4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Spyre Therapeutics, Inc.
NASDAQ:SYRE
$5.32B
Vera Therapeutics, Inc.
NASDAQ:VERA
$2.52B
Pharvaris N.V.
NASDAQ:PHVS
$2.29B
Celldex Therapeutics, Inc.
NASDAQ:CLDX
$2.20B
Intellia Therapeutics, Inc.
NASDAQ:NTLA
$1.70B
AbCellera Biologics Inc.
NASDAQ:ABCL
$1.66B
Biohaven Ltd.
NYSE:BHVN
$1.42B
Maze Therapeutics, Inc.
NASDAQ:MAZE
$1.39B
Zenas BioPharma, Inc.
NASDAQ:ZBIO
$860.10M
Upstream Bio, Inc.
NASDAQ:UPB
$339.04M
Who manages IMNM?
Immunome, Inc. (IMNM) lists 8 active executives. The top listed executive is Robert J. Lechleider, Chief Medical Officer.
Are IMNM insiders buying or selling?
Recent insider activity shows net buying of $71.80M.
Explore More
Continue the stock analysis
Jump to another research area for this company.